The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global influenza vaccine market exhibited XX growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Influenza vaccines, also known as flu shots, provide protection against various types of influenza viruses. They are available in several options, including inactivated influenza vaccine [IIV], recombinant influenza vaccine [RIV], and live attenuated influenza vaccine (LAIV). Their effectiveness can vary, depending on the patient's age and health status. Presently, governments of numerous countries have mandated immunization against influenza among children between six months and five years of age. This is escalating the need for influenza vaccines to reduce the high risk of developing severe flu complications and hospitalization among infants around the world.
The rising prevalence of diabetes, cancer, anemia, obesity, immune deficiencies, human immunodeficiency virus (HIV), metabolic diseases, kidney disease, neurological disorder, and chronic heart and lung disorders, such as bronchopulmonary dysplasia, cystic fibrosis, and asthma, is increasing the risk of developing influenza. This acts as a major factor bolstering the market growth. In addition, children under five years of age are usually at a high risk of complications from high fever, convulsions, and pneumonia. This, in confluence with growing concerns among parents about the well-being of their children, is positively influencing the demand for influenza vaccines. Moreover, as immune systems decline with age, the rising geriatric population worldwide is catalyzing the demand for influenza vaccines to prevent serious illness, the need for hospitalization, and the possibility of a heart attack. Several vaccines are also available that help boost immune response in adults over sixty-five years. Besides this, health agencies of numerous countries are introducing free seasonal influenza vaccination programs for people of all age groups, which is creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global influenza vaccine market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on vaccine type, type, technology, age group and route of administration.
Breakup by Vaccine Type:
Breakup by Type:
Breakup by Technology:
Breakup by Age Group:
Breakup by Route of Administration:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and SINOVAC.
|Base Year of the Analysis||2020|
|Segment Coverage||Vaccine Type, Type, Technology, Age Group, Route of Administration, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and SINOVAC.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at